An observational study in MPS IIIA, Sanfilippo Syndrome and Sanfilippo A, sponsored by Ultragenyx Pharmaceutical Inc. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Ultragenyx Pharmaceutical Inc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this observational study is to evaluate the long-term safety and effectiveness of rebisufligene etisparvovec for 10 years after rebisufligene etisparvovec administration.
The UX111-CL401 MPS IIIA Disease Monitoring Program is a prospective, multicenter, long term outcomes study to obtain safety and clinical outcomes data for 10 years after the administration of rebisufligene etisparvovec in either a clinical trial or post-marketing setting.
58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.
This study's planned enrollment of 55 is above the median of 30 across 24 observational studies indexed under Mucopolysaccharidosis III.
Browse Mucopolysaccharidosis III studies →Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
The DMP population comprises patients with MPS IIIA who received rebisufligene etisparvovec in a clinical trial or have been prescribed (or plan to receive) rebisufligene etisparvovec in a post marketing setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient who:
Group 1: Received rebisufligene etisparvovec in a prior interventional clinical trial.
May be enrolled upon completion of Study ABT-001 (Cohort 4) or end of study (EOS) or early termination (ET) visit from the prior clinical trial (Study ABT-003 or Study LTFU-ABO-102). OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in prior clinical study involving rebisufligene etisparvovec
Other: No Intervention
Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in a post-marketing setting
Other: No Intervention
No investigational/study product will be administered in this DMP.
Number of Participants with Serious Adverse Events (SAEs) Assessed as Related to Rebisufligene Etisparvovec by the Investigator and Targeted Adverse Events (Targeted AEs) Associated with Identified and Potential Risks of UX111 or AAV8 Gene Therapy
Time frame: 10 Years
Bayley Scales of Infant and Toddler Development Cognitive Raw Score Over Time
Time frame: 10 Years
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Oct 2038, 143 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ultragenyx Pharmaceutical Inc →